Compare Enveric Biosciences Inc (ENVB) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs TKO Group Holdings Inc — how do they compare? Enveric Biosciences Inc trades at $1.48 (market cap $6.80M), while TKO Group Holdings Inc trades at $178.93 (market cap $13.28B). The key difference: TKO Group Holdings Inc is far larger — about 1952.9× Enveric Biosciences Inc's market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and TKO Group Holdings Inc for 30 Days on average.
| ENVB | TKO | |
|---|---|---|
Market Cap | $6.80M | $13.28B |
Volume | 64,867 | 857,653 |
Sector | Health | Media |
52-Week High | $10.80 | $224.96 |
52-Week Low | $1.27 | $175.58 |
Typical Hold Time | 14 Days | 30 Days |
Enterprise Value | -$1.49M | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% on the day, with a bearish technical signal driven by moving averages. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten quarterly EPS expectations. Recent positive developments include a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in investor conferences.
The outlook is mixed; analyst consensus is 75% buy with strong earnings beats, but high negative ROE/ROA and operational cash burn pose significant risks. Investment opportunity hinges on successful drug development, while key risks include funding needs and clinical trial outcomes.
TKO trades at $181.54, up 1.62% on the day, but technical indicators signal a bearish trend. The company reported mixed Q2 2026 earnings, missing EPS estimates but beating on revenue, and raised full-year guidance. Strong analyst sentiment persists with an 89% buy rating and a $227 consensus price target, suggesting significant upside. Recent news highlights media rights strength and a declared dividend.
The outlook is cautiously optimistic given solid fundamentals and analyst support, but risks include execution on guidance and competitive pressures. The stock's high P/E of 63.73 indicates premium valuation, requiring sustained growth to justify. Near-term price action may be influenced by technical resistance and Q3 earnings results.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
